TLPPF Stock - Telix Pharmaceuticals Limited
Unlock GoAI Insights for TLPPF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $783.21M | $502.55M | $160.10M | $7.60M | $5.21M |
| Gross Profit | $509.68M | $314.39M | $29.34M | $-29,765,000 | $-16,877,000 |
| Gross Margin | 65.1% | 62.6% | 18.3% | -391.9% | -323.7% |
| Operating Income | $82.13M | $51.89M | $-91,930,000 | $-81,247,000 | $-49,253,000 |
| Net Income | $49.92M | $5.21M | $-104,079,000 | $-80,510,000 | $-44,887,000 |
| Net Margin | 6.4% | 1.0% | -65.0% | -1059.9% | -861.1% |
| EPS | $0.15 | $0.02 | $-0.34 | $-0.29 | $-0.17 |
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Visit WebsiteEarnings History & Surprises
TLPPFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 18, 2026 | — | — | — | — |
Q3 2025 | Aug 20, 2025 | $0.13 | $-0.01 | -105.1% | ✗ MISS |
Q1 2025 | Feb 20, 2025 | $0.09 | $0.07 | -24.2% | ✗ MISS |
Q3 2024 | Aug 22, 2024 | $0.09 | $0.02 | -75.4% | ✗ MISS |
Q2 2024 | May 22, 2024 | — | $0.04 | — | — |
Q2 2023 | Jun 30, 2023 | $0.04 | $-0.03 | -180.7% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | $-0.05 | $-0.07 | -44.1% | ✗ MISS |
Q2 2022 | Jun 30, 2022 | $-0.08 | $-0.16 | -94.4% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | $-0.06 | $-0.12 | -120.1% | ✗ MISS |
Q2 2021 | Jun 30, 2021 | $-0.09 | $-0.09 | -0.6% | ✗ MISS |
Q4 2020 | Dec 31, 2020 | $0.07 | $-0.08 | -208.1% | ✗ MISS |
Q2 2020 | Jun 30, 2020 | $-0.04 | $-0.05 | -11.8% | ✗ MISS |
Q4 2019 | Dec 31, 2019 | $-0.01 | $-0.05 | -349.4% | ✗ MISS |
Q2 2019 | Jun 30, 2019 | — | $-0.03 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.03 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.02 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.01 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.02 | — | — |
Q1 2017 | Jan 31, 2017 | — | $-0.01 | — | — |
Q2 2016 | Jun 30, 2016 | — | $0.01 | — | — |
Latest News
Telix Pharma Collaborates With Varian To Develop Clinical Applications That Combine Telix's Theranostic Products And External Beam Radiation Therapy
📈 PositiveTelix Pharma's ZIRCON-X Study Shows TLX250-CDx Imaging Could Alter Clinical Management In Nearly Half of Patients
📈 PositiveTelix's TLX250-CDx Included In Global Nuclear Medicine Guidelines For Renal Imaging
📈 PositiveTelix Pharmaceuticals Doses First Patient In Phase 1 Clinical Trial Of TLX090
📈 PositiveTelix Pharmaceuticals shares are trading higher. The company, yesterday, reported a year-over-year increase in Q3 revenue results and raised its FY25 revenue guidance.
📈 PositiveTelix Pharmaceuticals Sees Q3 Sales $206.000M
📈 PositiveTelix Pharmaceuticals Raises FY2025 Sales Guidance from $770.000M-$800.000M to $800.000M-$820.000M
📈 PositiveTelix Reports Q3 Revenue Of $206M Up 53% Year Over Year, Raises FY 2025 Guidance To $800M–$820M
📈 PositiveCORRECTION: UBS Analyst David Dai Maintained Buy Rating On Telix Pharmaceuticals And Lowered PT From $23 To $20
➖ NeutralTelix Pharmaceuticals shares are trading higher after the United States Centers for Medicare & Medicaid Services granted the company Transitional Pass-Through payment status for Gozellix.
📈 PositiveUS Centers For Medicare & Medicaid Services Grants Transitional Pass-Through Payment Status To Telix's Gozellix PSMA-PET Imaging Agent For Prostate Cancer
📈 PositiveUBS Maintains Buy on Telix Pharmaceuticals, Lowers Price Target to $20
📈 PositiveCitigroup Initiates Coverage On Telix Pharmaceuticals with Buy Rating, Announces Price Target of $22
📈 PositiveHC Wainwright & Co. Maintains Buy on Telix Pharmaceuticals, Lowers Price Target to $20
➖ NeutralReported Earlier, Telix Initiates Phase 3 BiPASS Trial In Australia And US To Advance PSMA-PET Imaging For Prostate Cancer Diagnosis
📈 PositiveTelix Pharmaceuticals shares are trading lower after JPMorgan on Thursday downgraded the stock from Overweight to Neutral.
📉 NegativeJP Morgan Downgrades Telix Pharmaceuticals to Neutral
➖ NeutralWedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target
📈 PositiveTelix Pharmaceuticals stock drops as SEC probes disclosures tied to cancer treatment
📉 NegativeFrequently Asked Questions about TLPPF
What is TLPPF's current stock price?
What is the analyst price target for TLPPF?
What sector is Telix Pharmaceuticals Limited in?
What is TLPPF's market cap?
Does TLPPF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to TLPPF for comparison